TY - JOUR
T1 - Outcomes after TIPS for Ascites and Variceal Bleeding in a Contemporary Era - An ALTA Group Study
AU - Advancing Liver Therapeutic Approaches (ALTA) Study Group
AU - Boike, Justin Richard
AU - Mazumder, Nikhilesh Ray
AU - Kolli, Kanti Pallav
AU - Ge, Jin
AU - German, Margarita
AU - Jest, Nathaniel
AU - Morelli, Giuseppe
AU - Spengler, Erin
AU - Said, Adnan
AU - Lai, Jennifer C.
AU - Desai, Archita P.
AU - Couri, Thomas
AU - Paul, Sonali
AU - Frenette, Catherine
AU - Verna, Elizabeth C.
AU - Rahim, Usman
AU - Goel, Aparna
AU - Gregory, Dyanna
AU - Thornburg, Bartley
AU - VanWagner, Lisa B.
N1 - Funding Information:
Potential competing interests: L.B.V. receives investigator-initiated and educational grant support and is on the speaker's bureau for W.L. Gore & Associates, the manufacturer of the TIPS Viatorr stent. J.R.B. receives investigator-initiated grant support from W.L. Gore & Associates. Study Highlights WHAT IS KNOWN
Funding Information:
Financial support: This study did not receive direct financial support. The ALTA Study Group however is funded by an investigator-initiated grant from W.L. Gore and Associates. This secondary analysis was funded by the National Heart, Lung, and Blood Institute grant number, K23 HL136891. The Northwestern Medicine Enterprise Data Warehouse (NMEDW) and Research Electronic Data Capture (REDCap) are funded, in part, by the National Center for Advancing Translational Sciences (NCATS) of the NIH research grant UL1TR001422 to the Northwestern University Clinical and Translational Sciences (NUCATS) Institute. The sponsor (W.L. Gore and Associates) had no input into the overall design and conduct of the ATLA Study. The funding agencies for the authors (NIDDK and NIA) played no role in the analysis of the data or the preparation of this manuscript.
Publisher Copyright:
© 2021 Wolters Kluwer Health. All rights reserved.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - INTRODUCTION:Advances in transjugular intrahepatic portosystemic shunt (TIPS) technology have led to expanded use. We sought to characterize contemporary outcomes of TIPS by common indications.METHODS:This was a multicenter, retrospective cohort study using data from the Advancing Liver Therapeutic Approaches study group among adults with cirrhosis who underwent TIPS for ascites/hepatic hydrothorax (ascites/HH) or variceal bleeding (2010-2015). Adjusted competing risk analysis was used to assess post-TIPS mortality or liver transplantation (LT).RESULTS:Among 1,129 TIPS recipients, 58% received TIPS for ascites/HH and 42% for variceal bleeding. In patients who underwent TIPS for ascites/HH, the subdistribution hazard ratio (sHR) for death was similar across all Model for End-Stage Liver Disease Sodium (MELD-Na) categories with an increasing sHR with rising MELD-Na. In patients with TIPS for variceal bleeding, MELD-Na ≥20 was associated with increased hazard for death, whereas MELD-Na ≥22 was associated with LT. In a multivariate analysis, serum creatinine was most significantly associated with death (sHR 1.2 per mg/dL, 95% confidence interval [CI] 1.04-1.4 and 1.37, 95% CI 1.08-1.73 in ascites/HH and variceal bleeding, respectively). Bilirubin and international normalized ratio were most associated with LT in ascites/HH (sHR 1.23, 95% CI 1.15-1.3; sHR 2.99, 95% CI 1.76-5.1, respectively) compared with only bilirubin in variceal bleeding (sHR 1.06, 95% CI 1.00-1.13).DISCUSSION:MELD-Na has differing relationships with patient outcomes dependent on TIPS indication. These data provide new insights into contemporary predictors of outcomes after TIPS.
AB - INTRODUCTION:Advances in transjugular intrahepatic portosystemic shunt (TIPS) technology have led to expanded use. We sought to characterize contemporary outcomes of TIPS by common indications.METHODS:This was a multicenter, retrospective cohort study using data from the Advancing Liver Therapeutic Approaches study group among adults with cirrhosis who underwent TIPS for ascites/hepatic hydrothorax (ascites/HH) or variceal bleeding (2010-2015). Adjusted competing risk analysis was used to assess post-TIPS mortality or liver transplantation (LT).RESULTS:Among 1,129 TIPS recipients, 58% received TIPS for ascites/HH and 42% for variceal bleeding. In patients who underwent TIPS for ascites/HH, the subdistribution hazard ratio (sHR) for death was similar across all Model for End-Stage Liver Disease Sodium (MELD-Na) categories with an increasing sHR with rising MELD-Na. In patients with TIPS for variceal bleeding, MELD-Na ≥20 was associated with increased hazard for death, whereas MELD-Na ≥22 was associated with LT. In a multivariate analysis, serum creatinine was most significantly associated with death (sHR 1.2 per mg/dL, 95% confidence interval [CI] 1.04-1.4 and 1.37, 95% CI 1.08-1.73 in ascites/HH and variceal bleeding, respectively). Bilirubin and international normalized ratio were most associated with LT in ascites/HH (sHR 1.23, 95% CI 1.15-1.3; sHR 2.99, 95% CI 1.76-5.1, respectively) compared with only bilirubin in variceal bleeding (sHR 1.06, 95% CI 1.00-1.13).DISCUSSION:MELD-Na has differing relationships with patient outcomes dependent on TIPS indication. These data provide new insights into contemporary predictors of outcomes after TIPS.
UR - http://www.scopus.com/inward/record.url?scp=85118283154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118283154&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000001357
DO - 10.14309/ajg.0000000000001357
M3 - Article
C2 - 34158464
AN - SCOPUS:85118283154
SN - 0002-9270
VL - 116
SP - 2079
EP - 2088
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 10
ER -